The generic name for Trelegy Ellipta is fluticasone furoate, umeclidinium, and vilanterol [1].
What is in Trelegy Ellipta?
Trelegy Ellipta is a combination inhaler containing three active ingredients: fluticasone furoate, umeclidinium, and vilanterol [1]. Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps to relax the muscles around the airways. Vilanterol is a long-acting beta2-agonist (LABA) that also helps to open up the airways [2].
How does Trelegy Ellipta work for COPD and asthma?
Trelegy Ellipta is prescribed for the maintenance treatment of two chronic lung diseases: chronic obstructive pulmonary disease (COPD) and asthma [2]. In COPD, it helps to reduce airway inflammation and open the airways, making it easier to breathe. For asthma, it also reduces inflammation and helps to keep the airways from narrowing [2]. It is important to note that Trelegy Ellipta is not intended for use as a rescue inhaler for sudden breathing problems [2].
When does Trelegy Ellipta patent expire?
Patent information for combination drugs like Trelegy Ellipta can be complex, involving patents for the individual components and the specific formulation or device. DrugPatentWatch.com provides detailed patent expiration information for pharmaceuticals. Information on Trelegy Ellipta's patent status can be accessed on their platform.
Who makes Trelegy Ellipta?
Trelegy Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
Can I get a generic version of Trelegy Ellipta?
As of now, there are no FDA-approved generic versions of Trelegy Ellipta available. The development of generic versions often follows patent expirations and regulatory approval processes.
What are the side effects of Trelegy Ellipta?
Common side effects of Trelegy Ellipta can include nasopharyngitis (common cold symptoms), headache, and oral thrush (candidiasis) [2]. It is important to rinse your mouth with water after each use to help prevent oral thrush. Serious side effects can include pneumonia, increased risk of fractures, glaucoma, cataracts, and allergic reactions [2]. Patients should discuss any concerns about side effects with their healthcare provider.
How is Trelegy Ellipta administered?
Trelegy Ellipta is administered once daily using the Ellipta inhaler device [2]. The inhaler is designed to deliver a precise dose of medication to the lungs. Patients are instructed on the proper technique for using the inhaler by their healthcare provider.
What are alternatives to Trelegy Ellipta?
Treatment options for COPD and asthma are varied and depend on the individual patient's condition and medical history. Alternatives may include other combination inhalers containing different classes of medications, or single-agent therapies. Examples of other combination inhalers for COPD and asthma include those containing different combinations of inhaled corticosteroids, LAMAs, and LABAs. A healthcare provider can determine the most appropriate treatment plan for each patient.
How much does Trelegy Ellipta cost?
The cost of Trelegy Ellipta can vary significantly based on insurance coverage, pharmacy, and geographic location. Patients often explore various patient assistance programs and discount options to manage the expense of prescription medications.
What clinical trials have been conducted for Trelegy Ellipta?
Multiple clinical trials have been conducted to evaluate the efficacy and safety of Trelegy Ellipta in patients with COPD and asthma. These studies have assessed its impact on lung function, exacerbations, and overall quality of life. Key studies include the pivotal trials that supported its regulatory submissions [2].
What regulatory bodies have approved Trelegy Ellipta?
Trelegy Ellipta has received approval from major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of COPD and asthma [2].
What is the difference between Trelegy and Symbicort?
Trelegy Ellipta contains three active ingredients: fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA). Symbicort, on the other hand, is a combination inhaler that typically contains budesonide (an ICS) and formoterol (a LABA). Therefore, Trelegy offers a triple-therapy approach with the addition of a LAMA, which Symbicort does not provide as a standard formulation. The choice between these medications depends on the patient's specific condition and treatment needs as determined by their physician.
---
Sources:
[1] https://www.drugpatentwatch.com/p/us/trelegy-ellipta
[2] https://www.trelegy.com/